封面
市場調查報告書
商品編碼
1386129

全球呼吸道病毒疫苗市場:趨勢、預測與競爭分析(-2030 年)

Respiratory Virus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

呼吸道病毒疫苗的趨勢與預測

預計2030年,全球呼吸道病毒疫苗市場規模將達到約135億美元,2024年至2030年年複合成長率為7.4%。該市場的主要促進因素是呼吸道病毒感染率上升、人們對疫苗效用的認知不斷提高,以及政府加快疫苗開發和普及的支出增加。全球呼吸道病毒疫苗市場的未來前景看好,診所、醫院、診所和藥局/商店市場有商機。

呼吸道病毒疫苗市場洞察

Lucintel 預測,由於去活化/殺死的免疫反應能夠刺激強烈且持久的免疫反應,預計在預測期內將出現最高成長。

在這個市場中,預計醫院將在預測期內實現最高成長。

由於強大的醫療基礎設施和政府資助,預計北美在預測期內將出現最高的成長。

市場規模/估計:以金額估計呼吸道病毒疫苗的市場規模(10億美元)

趨勢和預測分析:各細分市場和地區的市場趨勢(2018-2023)和預測(2024-2030)

細分分析:按類型、給藥途徑、適應症、最終用途和地區等不同細分市場估計呼吸道病毒疫苗的市場規模(十億美元)

區域分析:北美、歐洲、亞太地區和世界其他地區的呼吸道病毒疫苗市場細分

成長機會:按類型、給藥途徑、適應症、最終用途和呼吸道病毒疫苗市場區域分類的成長機會分析

策略分析:呼吸道病毒疫苗市場併購、新產品開發、競爭形勢等

基於波特五力模型的產業競爭實力分析

本報告回答了 11 個關鍵問題:

  • Q.1. 細分市場中最有前途和高成長的機會是什麼?
  • Q.2.哪個細分市場將以更快的速度成長?為什麼?
  • Q.3.您認為哪些地區未來會出現更快的成長?為什麼?
  • Q.4. 影響市場動態的主要因素有哪些?市場的主要挑戰和業務風險是什麼?
  • Q.5. 這個市場的商業風險和競爭威脅是什麼?
  • Q.6.這個市場有哪些新趨勢?為什麼?
  • Q.7.市場客戶需求有何改變?
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位?
  • Q.9.這個市場的主要企業有哪些?主要企業採取哪些策略配合措施來發展業務?
  • Q.10. 該市場上的競爭產品有哪些?由於材料或產品替代而導致市場佔有率下降的威脅有多大?
  • Q.11.過去年度發生了哪些併購事件,對產業產生了哪些影響?

目錄

第1章 執行摘要

第2章 全球呼吸道病毒疫苗市場:市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢(2018-2023)與預測(2024-2030)
  • 全球呼吸道病毒疫苗市場趨勢(2018-2023)與預測(2024-2030)
  • 全球呼吸道病毒疫苗市場:按類型
    • Inactivated/Killed
    • Live-Attenuated
    • Recombinant
  • 全球呼吸道病毒疫苗市場:依給藥途徑分類
    • 肌肉注射
    • 鼻內
    • 皮下的
  • 全球呼吸道病毒疫苗市場:依適應症分類
    • 流感
    • 麻疹
    • 流行性腮腺炎/德國麻疹
    • 新冠病毒
  • 全球呼吸道病毒疫苗市場:依最終用途分類
    • 診所
    • 醫院
    • 診所
    • 藥房/商店
    • 其他

第4章 市場趨勢與預測分析:按地區(2018-2030)

  • 全球呼吸道病毒疫苗市場區域分佈
  • 北美呼吸道病毒疫苗市場
  • 歐洲呼吸道病毒疫苗市場
  • 亞太呼吸道病毒疫苗市場
  • 其他地區呼吸道病毒疫苗市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球呼吸道病毒疫苗市場成長機會
    • 按給藥途徑的全球呼吸道病毒疫苗市場成長機會
    • 全球呼吸道病毒疫苗市場成長機會(按適應症)
    • 全球呼吸道病毒疫苗市場成長機會(依最終用途)
    • 全球呼吸道病毒疫苗市場成長機會(按地區)
  • 全球呼吸道病毒疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球呼吸道病毒疫苗市場產能擴張
    • 全球呼吸道病毒疫苗市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic
簡介目錄

Respiratory Virus Vaccine Trends and Forecast

The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030 with a CAGR of 7.4% from 2024 to 2030. The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.

A more than 150-page report is developed to help in your business decisions.

Respiratory Virus Vaccine by Segment

The study includes a forecast for the global respiratory virus vaccine by type, route of administration, indication, end use, and region.

Respiratory Virus Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Inactivated/Killed
  • Live-Attenuated
  • Recombinant

Respiratory Virus Vaccine Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Intramuscular
  • Intranasal
  • Subcutaneous

Respiratory Virus Vaccine Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Influenza
  • Measles
  • Mumps & Rubella
  • Coronavirus

Respiratory Virus Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Physician Offices
  • Hospitals
  • Clinics
  • Pharmacies/Stores
  • Others

Respiratory Virus Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Respiratory Virus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic

Respiratory Virus Vaccine Market Insights

Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.

Within this market, hospital is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.

Features of the Global Respiratory Virus Vaccine Market

Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).

Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the respiratory virus vaccine market size?

Answer: The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030.

Q.2 What is the growth forecast for respiratory virus vaccine market?

Answer: The global respiratory virus vaccine market is expected to grow with a CAGR of 7.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the respiratory virus vaccine market?

Answer: The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.

Q4. What are the major segments for respiratory virus vaccine market?

Answer: The future of the respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets.

Q5. Who are the key respiratory virus vaccine market companies?

Answer: Some of the key respiratory virus vaccine companies are as follows:

  • Sanofi
  • AstraZeneca
  • Merck
  • GlaxoSmithKline
  • Serum Institute of India
  • Moderna
  • Bavarian Nordic

Q6. Which respiratory virus vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.

Q7. In respiratory virus vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the respiratory virus vaccine market by type (inactivated/killed, live-attenuated, and recombinant), route of administration (intramuscular, intranasal, and subcutaneous), indication (influenza, measles, mumps & rubella, and coronavirus), end use (physician offices, hospitals, clinics, pharmacies/stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Virus Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Respiratory Virus Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Respiratory Virus Vaccine Market by Type
    • 3.3.1: Inactivated/Killed
    • 3.3.2: Live-Attenuated
    • 3.3.3: Recombinant
  • 3.4: Global Respiratory Virus Vaccine Market by Route of Administration
    • 3.4.1: Intramuscular
    • 3.4.2: Intranasal
    • 3.4.3: Subcutaneous
  • 3.5: Global Respiratory Virus Vaccine Market by Indication
    • 3.5.1: Influenza
    • 3.5.2: Measles
    • 3.5.3: Mumps & Rubella
    • 3.5.4: Coronavirus
  • 3.6: Global Respiratory Virus Vaccine Market by End Use
    • 3.6.1: Physician Offices
    • 3.6.2: Hospitals
    • 3.6.3: Clinics
    • 3.6.4: Pharmacies/Stores
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Respiratory Virus Vaccine Market by Region
  • 4.2: North American Respiratory Virus Vaccine Market
    • 4.2.2: North American Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.3: European Respiratory Virus Vaccine Market
    • 4.3.1: European Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.3.2: European Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.4: APAC Respiratory Virus Vaccine Market
    • 4.4.1: APAC Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.4.2: APAC Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
  • 4.5: ROW Respiratory Virus Vaccine Market
    • 4.5.1: ROW Respiratory Virus Vaccine Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
    • 4.5.2: ROW Respiratory Virus Vaccine Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Indication
    • 6.1.4: Growth Opportunities for the Global Respiratory Virus Vaccine Market by End Use
    • 6.1.5: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Respiratory Virus Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Respiratory Virus Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Virus Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Sanofi
  • 7.2: AstraZeneca
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Serum Institute of India
  • 7.6: Moderna
  • 7.7: Bavarian Nordic